NEWTOWN, PA — Helius Medical Technologies, Inc. (NASDAQ: HSDT) will exhibit for the third consecutive year at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The company plans to highlight a year of significant advancements in making its Portable Neuromodulation Stimulator (PoNS®) more accessible to those with multiple sclerosis (MS) who have difficulty walking.
The CMSC’s 38th Annual Meeting runs from May 29 to June 1 at the Music City Center in Nashville, TN. Attendees visiting booth 500 can learn about PoNS, a non-implantable device that delivers electrical stimulation through the tongue to aid gait improvement when combined with physical exercise.
Helius Chief Executive Officer Dane Andreeff emphasized the company’s commitment to increasing accessibility for PoNS. “From the beginning, we have prioritized getting PoNS to as many people with MS and gait deficit as possible,” Andreeff said. He noted that efforts to engage with insurers predated the commercial availability of the device. “Our achievements over the past two months have fueled real momentum. We’re eager to share the latest good news about PoNS and its availability.”
Revolutionizing MS Treatment: The PoNS Breakthrough
This device represents a new frontier in MS treatment. Unlike traditional methods, PoNS provides a novel approach by utilizing neuromodulation to stimulate the brain through the tongue. This method aims to rewire neural pathways and improve motor function. The combination of PoNS with rehabilitative exercises offers a potential lifeline for many MS patients struggling with mobility.
For the general public, this innovation could mean a significant shift in the quality of life for MS sufferers. Mobility issues are one of the most debilitating symptoms of MS, affecting not only physical health but also emotional well-being and independence. A device like PoNS, which aids in mobility restoration, can dramatically change these patients’ daily lives.
Furthermore, Helius’s proactive engagement with insurers is crucial. Accessibility to such devices hinges not just on regulatory approval but also on insurance coverage. By securing agreements with insurers, Helius ensures that more patients can benefit from PoNS without prohibitive costs.
For investors and stakeholders, the company’s recent successes mark a promising trajectory. Effective treatments for chronic conditions like MS represent a significant market opportunity. Positive developments in accessibility and insurance negotiations enhance the commercial viability of PoNS, potentially driving Helius’s growth.
In summary, Helius Medical Technologies’ participation in the CMSC Annual Meeting underscores its commitment to advancing MS treatment. By increasing the accessibility of PoNS, the company is poised to make a substantial impact on the lives of MS patients, offering hope and improved mobility through innovative technology.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.